

Pentamidine

NOT RECOMMENDED AS AN
ESSENTIAL MEDICINE

Section: [6. Anti-infective medicines](#) > [6.5. Antiprotozoal medicines](#) > [6.5.2. Antileishmaniasis medicines](#)

EMLc

ATC codes: [P01CX01](#)

| | |
|--------------------------|---|
| Indication | Visceral leishmaniasis ICD11 code: 1F54.0 |
| INN | Pentamidine |
| Medicine type | Chemical agent |
| List type | Complementary (EML) (EMLc) |
| Formulations | Parenteral > General injections > IM: 200 mg (as isetionate) ; 300 mg (as isetionate) |
| EML status history | First added in 1977 (TRS 615) Changed in 1979 (TRS 641) Changed in 1987 (TRS 770) Changed in 1997 (TRS 882) Changed in 2003 (TRS 920) Changed in 2007 (TRS 950) Removed in 2009 (TRS 958) |
| Sex | All |
| Age | Also recommended for children |
| Therapeutic alternatives | The recommendation is for this specific medicine |
| Patent information | Patents have expired in most jurisdictions Read more about patents . ↗ |
| Wikipedia | Pentamidine ↗ |
| DrugBank | Pentamidine ↗ |

Summary of evidence and Expert Committee recommendations

The EMLc Subcommittee had recommended the deletion of pentamidine for this indication as it was no longer used for visceral leishmaniasis in children. The Committee reviewed Section 6.5.2, medicines for leishmaniasis, for concordance between the EML and EMLc and, on the advice of the WHO Department of Control of Neglected Tropical Diseases (NTD), recommended pentamidine be also deleted from the EML.

